Aqua Medical Lands Series B for PIMA Diabetes Trial

Relevance Ventures is putting Series B capital behind Aqua Medical's attempt to convert familiar endoscopy infrastructure into evidence for a new type 2 diabetes treatment. The September 23, 2026 financing is described only as multimillion-dollar, so the exact amount remains undisclosed.

The round is intended to support completion of Aqua Medical's U.S. RESTORE-1 pilot study and preparations for a planned pivotal trial, subject to regulatory authorization. That is the consequential part of the announcement: the company has moved beyond an early device concept, but it has not crossed the clinical and regulatory boundary required for a diabetes indication.

Aqua Medical has an FDA-cleared radiofrequency vapor ablation system for its indicated gastrointestinal use. Its Proximal Intestinal Mucosal Ablation procedure, known as PIMA, is investigational for type 2 diabetes. Aqua Medical says the safety and effectiveness of that use have not been established.

What the Series B finances

Relevance Ventures led the financing and did not disclose the exact investment amount or other participating investors. Dean Newton, the firm's chairman and general partner, joined Aqua Medical's board as part of the transaction.

The capital is earmarked for two related jobs: completing RESTORE-1 and preparing for a planned pivotal study. The first produces U.S. pilot evidence. The second requires Aqua Medical to turn that evidence into a trial and regulatory plan capable of supporting a larger claim.

Aqua Medical previously completed a $15.5M Series A in 2020. That round included an $8.2M final tranche led by ShangBay Capital, with Ithaka Partners and ForMED Ventures participating. Because the Series B amount is undisclosed, Aqua Medical's current total funding cannot be calculated from verified public figures.

How Aqua Medical's PIMA procedure works

Aqua Medical's system uses radiofrequency energy to create heated water vapor that travels through a proprietary catheter placed through an endoscope. For PIMA, the procedure targets proximal intestinal mucosa, based on the hypothesis that treating that tissue may change metabolic signaling associated with insulin resistance.

The procedure is designed to fit into an endoscopy workflow without incisions or fluoroscopy. That operating model matters commercially because a therapy that requires entirely new clinical infrastructure faces a different adoption burden from one designed around equipment and specialists already inside gastrointestinal care.

The mechanism is still being tested. Aqua Medical's own regulatory notice says the RFVA system is not cleared for type 2 diabetes and is not currently available for sale. The FDA's 510(k) database records the system's substantially-equivalent decision for an endoscopic electrosurgical GI use. That clearance cannot be carried over as proof that PIMA treats diabetes.

What the clinical evidence says

The U.S. RESTORE-1 study is registered as NCT07355270 and is evaluating safety, tolerability, and effectiveness in adults with type 2 diabetes. Aqua Medical reported treating the first U.S. patient at UNC Health in July 2026 after international clinical development.

The strongest publicly available independent evidence is a peer-reviewed first-in-human pilot study. It enrolled 27 patients, with 25 receiving the treatment dose. Researchers reported no serious adverse events, technical success in all attempted procedures, and preliminary reductions in HbA1c.

Those findings are encouraging within the limits of the study. The trial was small, nonrandomized, open-label, single-center, and uncontrolled. Its authors said it was not adequately powered to determine efficacy and that larger studies would be needed across different patient populations. RESTORE-1 is part of that next evidence layer, not a formality after a settled result.

The leadership and investor handoff

Robert "Bob" Haggerty became Aqua Medical's president and CEO in July 2026. The company's current leadership page highlights more than three decades of Haggerty's gastroenterology experience, including work commercializing radiofrequency ablation for Barrett's esophagus. Founder Virender K. Sharma, MD remains founder, CMO, and director, while Greg Wilson, Scott McGill, Raj Nihalani, MD, and Alina Stoica support the financial, engineering, medical, and clinical-research functions.

Relevance Ventures invests in early-growth health companies and frames its strategy around prevention across personal, digital, community, and financial health. The firm announced the Aqua Medical investment alongside its participation at NAFOA's Fall Finance & Tribal Economies Conference in Santa Fe. That setting adds a capital-access dimension to the transaction, particularly because Relevance is Native American-owned and connects the investment to health challenges affecting Native communities.

The investor fit is strategically legible, but it does not reduce the clinical burden. Dean Newton's board seat puts Relevance closer to the decisions that will shape trial execution, regulatory preparation, and financing discipline as Aqua Medical moves through a more expensive phase of development.

Why this funding matters

Type 2 diabetes already has pharmaceutical, lifestyle, and surgical treatment pathways. Aqua Medical is trying to establish a procedure-based option between chronic medication escalation and more invasive surgery. That position is commercially attractive precisely because it is clinically difficult.

The company must show that PIMA produces meaningful and durable outcomes, that its safety profile holds in broader U.S. use, and that the procedure can be delivered consistently within real endoscopy settings. It must also keep the distinction between the RFVA system's existing GI clearance and PIMA's investigational diabetes use clear as the clinical story develops.

This Series B gives Aqua Medical time and capital to do that work. The next value-creating event will not be a sharper description of the platform. It will be evidence strong enough to tell physicians, regulators, patients, and future investors where this procedure belongs in diabetes care.